Mark C. McKenna served as Chairman and Chief Executive Officer of Prometheus Biosciences (Nasdaq: RXDX) from 2019-2023. Prometheus Biosciences was a clinical stage biotechnology company which created the first precision therapeutics for immune-mediated diseases which was acquired by Merck for $10.8B in June of 2023. The acquisition represented the largest M&A takeout of pre-phase 3 company. Mr. McKenna brings more than 20+ years of experience and strategic leadership from the Pharmaceutical, Medical Device, MedTech, Consumer and Diagnostics sectors. While at Prometheus, Mr. McKenna raised more than a $1B in private and public financing, led the top performing biotech IPO of 2021 and top performing biotech stock of 2022 and 2023(prior to transaction close). Early investors of Prometheus earned more than 25X return on capital. Mr. McKenna currently serves as Chairman of Apogee Therapeutics. Prior to Prometheus, Mr. McKenna was a corporate officer of Bausch Health and served as President of the subsidiary Salix Pharmaceuticals. There he revitalized the gastroenterology business with a series of strategic acquisitions and product launches, doubling revenue to exceed $2B while enhancing operating margins. Earlier, Mr. McKenna served at Bausch + Lomb for more than a decade, most recently as SVP and General Manager of the US Vision Care business where he significantly grew revenue by 22% CAGR in an otherwise flat market. He began his career at Johnson & Johnson and held several positions of increasing responsibility. Mr. McKenna holds a degree in Marketing from Arizona State University and a MBA from Azusa Pacific University. Mr. McKenna also completed the Wharton’s Fellows program at the University of Pennsylvania school of business. Mr. McKenna is passionate about solving big problems in medicine and is regularly featured on CNBC’s Mad Money and Bloomberg radio. In addition, Mr. McKenna is a frequent guest speaker at the Longwood Healthcare conference and other industry thought-leader events. In 2023, he was selected as EY’s Entrepreneur of the year, recognizing his contributions to advancement of entrepreneurship and science.